Sanofi (NASDAQ:SNY) Raised to Strong-Buy at StockNews.com

StockNews.com upgraded shares of Sanofi (NASDAQ:SNY) from a buy rating to a strong-buy rating in a research report report published on Thursday.

Separately, Argus boosted their price objective on shares of Sanofi from $55.00 to $60.00 and gave the stock a buy rating in a research report on Friday, July 26th. Three analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus target price of $57.50.

Sanofi Trading Up 2.7 %

Shares of SNY opened at $53.05 on Thursday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The company has a market cap of $134.36 billion, a price-to-earnings ratio of 26.66, a PEG ratio of 1.50 and a beta of 0.59. The stock has a fifty day moving average price of $49.51 and a two-hundred day moving average price of $48.67. Sanofi has a 52-week low of $42.63 and a 52-week high of $55.72.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. The business had revenue of $10.75 billion during the quarter, compared to analysts’ expectations of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.95 earnings per share. Analysts predict that Sanofi will post 4.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in SNY. Cardinal Capital Management lifted its stake in Sanofi by 0.3% in the fourth quarter. Cardinal Capital Management now owns 58,854 shares of the company’s stock valued at $2,927,000 after buying an additional 201 shares during the period. TCTC Holdings LLC boosted its stake in Sanofi by 28.0% during the 1st quarter. TCTC Holdings LLC now owns 960 shares of the company’s stock worth $47,000 after acquiring an additional 210 shares during the last quarter. Daiwa Securities Group Inc. grew its holdings in Sanofi by 3.4% during the fourth quarter. Daiwa Securities Group Inc. now owns 6,541 shares of the company’s stock valued at $325,000 after purchasing an additional 216 shares during the period. HB Wealth Management LLC increased its stake in Sanofi by 3.7% in the second quarter. HB Wealth Management LLC now owns 6,166 shares of the company’s stock valued at $299,000 after purchasing an additional 221 shares in the last quarter. Finally, Wynn Capital LLC raised its holdings in Sanofi by 4.5% in the first quarter. Wynn Capital LLC now owns 5,266 shares of the company’s stock worth $256,000 after purchasing an additional 226 shares during the period. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.